SGLT2 inhibition, acylcarnitines and heart failure: a Mendelian randomization study.

ABSTRACT:

Objective

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are guideline-recommended agents for treating heart failure (HF), but the role of metabolomic biomarkers in underlying mechanisms, particularly acylcarnitines, remains unclear. This study examined the associations of acylcarnitines with SGLT2 inhibition and incident HF.

Methods

This subcohort study included 2178 participants from the prospective China Kadoorie Biobank without cardiovascular disease, diabetes or cancer at baseline. Plasma levels of 40 acylcarnitines were quantified using targeted mass spectrometry-based platforms. The impact of genetically predicted random plasma glucose (RPG) via SGLT2 inhibition on acylcarnitines was assessed with Mendelian randomization (MR). The associations of acylcarnitines wit

SUBMITTER: Wu Z 

PROVIDER: S-EPMC12406923 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature